Navigation Links
Spherics, Inc. Assigns Assets to Joseph F. Finn, Jr., C.P.A.
Date:8/4/2008

WELLESLEY HILLS, Mass., Aug. 4 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn") announced today that the assets of Spherics, Inc. ("Spherics") had been assigned to him on July 28, 2008 for the benefit of creditors. An Assignment for the Benefit of Creditors is a common law procedure, wherein Finn will liquidate the assets, which consist primarily of pharmaceutical IP, by means of a sealed bid auction on October 10, 2008.

Persons interested in bidding must sign a Confidential Disclosure Agreement ("CDA") obtained from Finn's office. They will then receive a bid package and access to the Spherics electronic data room.

About Spherics

Spherics has built a strong intellectual property position around its drug delivery technologies and products. The Company has a broad range of issued US and international patents through exclusive licenses from Brown University. These patents cover polyanhydride-based bioadhesive polymers and PIN. In addition to these issued patents, Spherics has filed numerous applications covering compositions of matters of its proprietary polymers (SPHEROMERS), novel oral delivery systems (including BIOGIT, BIOROD and PIN), manufacturing methods, methods of use, formulations and product compositions.

About Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr. is the founding partner of the firm Finn, Warnke & Gayton, Certified Public Accountants of Wellesley Hills, Massachusetts. He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors and liquidating agent for a corporation. He has been involved in a number of loan workouts and bankruptcy cases for thirty-four (34) years. His most recent Assignment for the Benefit of Creditors in the Biotech field was ActivBiotics, Inc.


'/>"/>
SOURCE Spherics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc.
2. BioEnergy International, LLC Acquires Assets of OmniGene Bioproducts, Inc.
3. Favrille Announces Resolution of Debt Obligations and Plans for Maximizing Assets
4. Veridex Announces Agreement to Acquire the Assets of Immunicon Corporation
5. VaxGen Sells Anthrax Vaccine Program and Related Assets and Technology to Emergent BioSolutions, Inc.
6. Derma Sciences Announces Agreement With MedAssets for MEDIHONEY(TM) Wound & Burn Dressings
7. bioMETRX, Inc. Initiates Integration of Personnel and Assets of Sequiam Corp.
8. Ortho Biotech Oncology Research & Development Unites Johnson & Johnson Biopharmaceutical Oncology R&D Assets
9. ActivBiotics Intellectual Property Assets, Including Drug Product Candidates, Sold for $3.5 Million
10. ActivBiotics Set to Sell Proprietary Assets, Including Drug Product Candidates, on March 14, 2008
11. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... CytRx Corporation (NASDAQ: CYTR ), ... today announced the appointment of Earl Warren Brien ... private healthcare investor, to its Board of Directors. ... and strategic experience at the highest level," said ... one of the world,s leading orthopedic surgeons, Dr. Brien ...
(Date:12/2/2016)... ... 01, 2016 , ... Aerocom Healthcare ( http://www.aerocomhealthcare.com ), representing ... its chain-of-custody solution for tracking and securing medications at booth 676 at the ... , Aerocom has a proven solution for tracking medications via its system from ...
(Date:12/2/2016)... ... December 01, 2016 , ... Orthogonal, a Chicago-based medical device ... Class II 510(k) clearance for their flagship medical device, SimplECG. , With this ... devices that rely on cloth-based nanosensors. While other companies have attempted to focus ...
(Date:12/2/2016)... The immunohistochemistry (IHC) market is projected to reach ... during the forecast period of 2016 to 2021 dominated by immunohistochemistry ... the largest share of immunohistochemistry (IHC) market, by end user.   ... , , ... across 225 pages, profiling 10 companies and supported with 181 tables ...
Breaking Biology Technology:
(Date:11/19/2016)... 2016 Securus Technologies, a leading provider of ... investigation, corrections and monitoring, announced today that it has ... have an independent technology judge determine who has the ... tech/sophisticated telephone calling platform, and the best customer service. ... most of what we do – which clearly is ...
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, Inc. ... therapeutics focused on the gut microbiome, today announced ... 25,000,000 shares of its common stock and warrants ... at a price to the public of $1.00 ... Synthetic Biologics from the offering, excluding the proceeds, ...
(Date:6/27/2016)... Research and Markets has announced the addition ... to their offering. The report ... to grow at a CAGR of 12.28% during the period 2016-2020. ... in-depth market analysis with inputs from industry experts. The report covers ... The report also includes a discussion of the key vendors operating ...
Breaking Biology News(10 mins):